ReviewDrug design, development and therapy2025
Cyanidin and Cyanidin-3-Glucoside Alleviate Peptic Ulcer Disease: Insights from in vitro, and in vivo Studies.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cyanidin-3-O-glucoside Alleviates Inflammatory Bowel Disease by Targeting the NF-κB Pathway and is Associated With Alterations in 1-DNJ.Molecular nutrition & food research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptic ulcer disease (PUD) remains a significant global health issue, affecting millions despite a decrease in overall prevalence. However, complications continue to persist, with substantial mortality rates in regions like India and China. Current treatments, though effective, have limitations, driving interest in plant-derived therapy. Anthocyanins, including cyanidin and cyanidin-3-glucoside (C3G), are known for their antioxidant and anti-inflammatory properties. This study aims to explore the potential of cyanidin and C3G in alleviating PUD, focusing on their mechanisms of action and therapeutic efficacy in preclinical studies. Articles were searched in Scopus and PubMed databases and filtered for publication from 2014 to 2024, resulting in 89 articles from Scopus and 11 articles from PubMed. The articles were further screened by title, abstract, and full text, resulting in 6 articles. Cyanidin and C3G were described to be able to alleviate PUD by inhibiting the cytokine pro-inflammatory, reducing inflammation in gastric mucosa, and reducing lipid peroxidation in the gastric mucosa. These compounds have proven effective in managing other health problems, including peptic ulcers, but more in-depth exploration in clinical settings is required to confirm therapeutic potential in humans. It is necessary to validate the therapeutic efficacy and safety in human populations. This review provides an overview of preclinical studies of cyanidin and C3G, such as in vitro and in vivo, focusing on mechanism of action or their effectiveness in alleviating peptic ulcers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.